



Yu Mi Kang

Harvard Medical School, USA

• Education

Period	Affiliation	Position
– 2024-Present	Harvard School of Public Health, Boston, MA, USA	Masters of Public Health in Clinical Effectiveness
– 2023-2015	University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea	Ph.D.
– 2006-2010	Chonbuk National University College of Medicine, Jeonju, Korea	M.D.
– 2002-2005	University of Toronto	B.Sc.

• Affiliations / Experience

Period	Affiliation	Position
– 2022-2025	Harvard Medical School	Senior Interdisciplinary Fellow (US)
– 2019-2022	Yale University School of Medicine	Internal Medicine Residency (US)
– 2017-2019	Asan Medical Center	Instructor
– 2015-2017	Asan Medical Center	Fellow (Endocrine & Metabolism)
– 2011-2015	Asan Medical Center	Internal Medicine Residency

• Committee Memberships

- International Advisory Board Member, Korean Society of Lipid and Atherosclerosis
- Korean Society for the Study of Obesity
- American Diabetes Association
- American Heart Association
- European Society of Cardiology

• Publications

- Patel SM, Kang, YM et al. Sodium Glucose Co-transporter 2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis. *Circulation*. 2024 Apr 7 Online ahead of print. doi: 10.1161/CIRCULATIONAHA.124.069568
- Kang YM, Cho YK, Lee J, Lee SE, Lee WJ, Park JY, Kim YJ, Jung CH, Nauck MA. Asian Subpopulations May Exhibit Greater Cardiovascular Benefit From Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A Meta-Analysis of Cardiovascular Outcome Trials. *Diabetes Metab J* 2019 Aug;43(4):410-421. doi: 10.4093/dmj.2018.0070. PMID 3060459
- Kang YM, Cho YK, Lee SE, Park JY, Lee WJ, Kim YJ, Jung CH. Cardiovascular Diseases and Life Expectancy in Adults with Type 2 Diabetes; A Korean National Sample Cohort Study. *J Clin Endocrinol Metab* jc.2017-00643. DOI: <https://doi.org/10.1210/jc.2017-00643>. PMID 28911137